Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Thursday, 12 / 09 / 2021

Abstract

Hepatitis B and Hepatitis C Reactivation in the Biologic Era

Lizza Bojito-Marrero and Nikolaos Pyrsopoulos*

Division of Gastroenterology and Hepatology, Rutgers New Jersey Medical School, Newark, USA

Abstract

Hepatitis B (HBV) and hepatitis C (HCV) reactivation may occur after the use of biologic agents. During the last decade, utilization of biologics has changed the fate of many treated for cancer, autoimmune and connective tissue disease, maintenance of transplanted organs, and the prevention of graft-versus-host disease among others. HBV reactivation has been reported in up to 50% of HBV carriers undergoing immunosuppressivetherapy, and there is emerging data pointingtowards an increased risk for HCV reactivation. If reactivationof HBV and HCVoccurs, the spectrum of clinical manifestationscan range from asymptomatic hepatitis flares to hepaticdecompensation, fulminant hepatic failure, and death.Therefore, identifying patients at risk and early diagnosis areimperative to decrease significant morbidity and mortality. Thepurpose of this article is to review the pathophysiology of thereactivation of HBV and HCV infection in patients receivingbiologic therapies and the approaches used to diagnose,prevent, and treat HBV and HCV reactivation.

Doi: 10.14218/JCTH.2014.00033
Journal of Clinical and Translational Hepatology 2014 vol. 2 Pages: 240-246
[PDF Full-text ]

 logo